Prolia's annual sales are expected to be 100 billion won

Sales of follow-up drug Evenity are also expected.

Prolia dominated the osteoporosis market with accumulated sales of 83.8 billion won in the third quarter

Evenity ranks second in the osteoporosis market, 47% in a year ↑

Prolia & Evenity

Amgen's Prolia, which dominated the osteoporosis treatment market, is further strengthening its dominance system.

 

Sales are expected to surpass 100 billion won by the end of this year.

 

Evenity, a generic for Prolia, is also rapidly increasing its sales.

 

It has grown into the second-largest product in the osteoporosis treatment market in less than two years since the salary was applied in December 2020.

 

According to IQVIA, a pharmaceutical market research firm, Prolia's cumulative sales in the third quarter of this year were 83.8 billion won.

 

It increased by 28.6% compared to the same period last year-on-year.

 

Prolia is a mechanism drug that inhibits bone absorption.

 

It has become the first standard treatment for osteoporosis due to its superior effectiveness and convenience of administration compared to BP, which has been widely used in the past.

 

It is difficult to take BP for patients, such as taking a sufficient amount of water on an empty stomach 1 to 2 hours before a meal and not lying down for at least 30 minutes after taking it.

 

It was difficult for patients to continue to take medicine because side effects such as gastrointestinal disorders may occur when taking it for a long time.

 

Prolia only needs to be administered once every six months.

 

Even after 10 years of long-term treatment, the effect of continuous bone density improvement and consistent safety profile were confirmed.

 

Prolia's beneifit was applied only to the secondary treatment in 2017.

 

From April 2019, the range of benefits has been expanded to primary treatments.

 

Sales rose vertically shortly after the benefit increase.

 

Prolia's sales, which stood at only 14.3 billion won in 2018, more than tripled in a year to 47.3 billion won in 2019.

 

It has been steadily increasing to 75.1 billion won in 2020 and 92.1 billion won in 2021.

 

This year, sales of more than 80 billion won in the third quarter are expected to surpass 100 billion won at the end of the year.

 

During this period, Prolia's price was reduced by 17.6% on three occasions.

 

The drug price, which was 215,678 won at the time of initial registration, fell to 190,000 won in April 2019, 177,650 won in December 2020 and 168,800 won in July this year.

 

As usage soared, drug prices were lowered by PVA.

 

Considering the reduction in drug prices, it is possible to estimate that Prolia's use at the prescription site has increased significantly than sales growth.

 

It is analyzed that the expansion of benefits and the strengthening of sales power also contributed to Prolia's growth.

 

Amgen has been selling Prolia with Chong Kun Dang since September 2017.

 

Amgen Korea is in charge of sales and marketing of Prolia at hospitals and Chong Kun Dang at clinics.

 

Evenity's rise, released as Prolia's generic, is steeper.

 

The cumulative sales in the third quarter of this year were 12.2 billio wonn, up 47.4% from the cumulative 8.3 billion won in the third quarter of last year.

 

Evenity is a bone formation agent with a dual effect of promoting bone formation and inhibiting bone absorption.Amgen is devising Evenity's positioning strategy as sequential administration from Evenity to Prolia .

 

Evenity, which was granted in June 2019, was registered in December 2020.

 

Even before the registration, the drug received great attention at the prescription site.

 

It generated 3.8 billion won in sales in 2020.

 

It has been growing more rapidly since the benefit registration.

 

In 2021, sales more than tripled in a year to 12.3 billion won.

 

Until the third quarter of this year, sales were almost the same as last year.

 

It is expected to record sales of more than 15 billion won at the end of the year.

 

As Amgen's two products made strides, sales of existing BP formulations were low.

 

Eli Lilly Forsteo's cumulative sales in the third quarter of this year were 9.7 billion won.

 

It remains at the same level as last year.

 

The cumulative sales of Hanmi Pharmaceutical's RaboneD in the third quarter decreased by 1.5% from 7.4 billion won last year to 7.3 billion won this year.

 

The rest of the products have a bigger drop in sales.

 

Daewoong Zoledronic Acid saw its sales fall 33.6% from 7.8 billion won to 5.2 billion won during the period.

 

Jeil's Bonviva and Bonviva Plus fell 21.3% from 8.1 billion won to 6.4 billion won.

 

Since October, Jeil has taken over the domestic rights of Bonviva and Bonviva Plus from Handok.

 

Handok has been in charge of Bonviva's domestic sales and marketing for the past seven years.